胎児頻脈に対するソタロール投与量最適化:妊娠生理学的薬物動態(PBPK)モデル研究
Hedwig van Hove1, Joyce E M van der Heijden1, Anne van Uden1
1Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
Prenatal diagnosis
|February 27, 2026
まとめ
胎児頻脈に対するソタロール投与量の最適化は極めて重要である。妊娠生理学的薬物動態(PBPK)モデルは、母体の毒性を最小限に抑えながら胎児治療を改善する1日400mg未満の投与量、または分割投与量を示唆している。
科学分野:
- 薬理学; 母体胎児医学; 計算モデリング
背景:
- 胎児頻脈は妊娠中の効果的な治療を必要とします。; ソタロールは使用されていますが、有効性と母体の安全性のバランスをとるためには慎重な投与量が必要です。; 妊娠は薬物動態を変化させるため、最適化された投与戦略が必要です。
研究 の 目的:
- 妊娠生理学的薬物動態(PBPK)モデルを用いた胎児頻脈に対する最適化されたソタロール投与戦略を確立すること。; 母体のQT延長リスクを最小限に抑えながら、胎児治療濃度を最大化する投与レジメンを特定すること。
主な方法:
- 生理学的変化と胎盤移行を組み込んだ妊娠PBPKモデルの開発と検証。; 現在のソタロール投与推奨事項を評価し、代替シナリオを検討するためのシミュレーション。; ターゲット範囲の定義:母体濃度<2.5 mg/L、胎児Ctrough 0.4-1.0 mg/L。
主要な成果:
- モデル予測は既存の母体および胎児曝露データと一致しました。; 1日480mg投与では、母体濃度の16%が毒性閾値を超え、胎児治療レベルは90%でした。; 投与量を1日400mgに減らすと、母体の過剰曝露は0.1%に減少し(胎児治療レベル87%)ました。; 480mgを3回に分割して投与すると、母体の過剰曝露は0.3%に減少し、胎児目標達成率は95%でした。
結論:
- 妊娠PBPKモデリングは、胎児ソタロール療法を効果的に最適化します。; 1日あたりのソタロール投与量は400mg以下が推奨されます。; 240mg以上の投与量を3回に分割して投与すると、胎児の有効性と母体の安全性が最適化されます。
関連する概念動画
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drug Dosing: Infants and Children
434
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
434
Dosage Regimens: Partial Pharmacokinetic Parameters
229
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
229
Pharmacodynamic Models: Logarithmic Concentration–Effect Model
44
The log-linear model is a pharmacological framework used to describe the relationship between drug concentration and its effect. This model is particularly relevant when the observed effects range between 20% and 80% of the drug’s maximum effect (Emax), where a near-linear relationship is observed between the log of drug concentration and the measured effect. However, the log-linear model does not predict the maximum possible effect (Emax) or the effect at zero drug concentration,...
44
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
41
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
41


